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ABSTRACT
PURPOSES: Glucose disturbances are common in patients with coronary artery disease (CAD), however, 
usually, they remain undiagnosed. The aim of this study was to estimate the newly-diagnosed glucose ab-
normalities in patients undergoing coronary angiography for known or suspected CAD.
MATERIAL AND METHODS: A routine oral glucose tolerance test (OGTT) was applied in 96 consecutive 
patients without previous history of type 2 diabetes mellitus (T2DM) undergoing coronary angiography. 
Glucose tolerance was defined according to WHO-2006 criteria by OGTT performed within a week after hos-
pital discharge.
RESULTS: Glucose disturbances prevailed over normoglycemia as 64,58% of the patients demonstrated hy-
perglycemia while 35,42% presented with normal glucose tolerance (NGT). Overall, 120 min-hypеrglycemia 
(≥7,8 mmol/L) was found out in 52,08% of the participants and only 12,5% of the cases had isolated fasting 
hyperglycemia (fasting plasma glucose, FPG ≥6,1 mmol/L and postchallenge glucose <7,8 mmol/L). Based 
on plasma glucose values such as FPG and 2-hour post-OGTT glucose, the proportion of patients with newly-
diagnosed T2DM, impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) was 26,04%, 28,12% 
and 10,42 %, respectively. Some 20% of the newly-diagnosed T2DM patients reached a diagnostic FPG value 
only, 32% reached 120 min.-plasma glucose (PG) value only while 48% met combined criteria.
CONCLUSION: Glucose abnormalities identified by OGTT are more common than normoglycemia - in 
64,58% versus 35,42% of the patients undergoing coronary angiography for known or suspected CAD. This 
finding strongly suggests that OGTT is the most valuable tool for the early detection of disturbed glucose 
regulation and should be performed routinely in the patients with known or suspected CAD.
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INTRODUCTION
Glucose abnormalities are widespread among 
patients with coronary artery disease (CAD) and 
have serious prognostic implications. In fact, 
disturbed glucose metabolism is more prevalent than 
normoglycemia in CAD patients without known 
diabetes mellitus and exceeds 60% (1,7,8,10,12,16). 
Importantly, in the general population, oral glucose 
tolerance test (OGTT) doubles the number of patients 
diagnosed with diabetes mellitus towards fasting 
plasma glucose (FPG) (3,5% versus 7,3%) (3) whereas 
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in the coronary population there may be a fivefold 
increased difference (5,3% versus 26,9%) (7). All the 
stages of abnormal glucose metabolism, even modestly 
elevated but not within diabetic range glucose levels, 
carry an increased risk of cardiovascular morbidity 
and mortality (4,14). Impaired fasting glycose (IFG) 
and impaired glucose tolerance (IGT) are forms of 
prediabetes characterized by fasting and postprandial 
hyperglycemia, respectively. It is noteworthy that the 
patients with glucose abnormality may have normal 
fasting but elevated postchallenge glycemia during 
OGTT, and vice versa. 
Two-thirds of the patients with CAD and 
positive OGTT would remain undetected if only 
FPG is measured (2). The severity of postchallenge 
hyperglycemia closely correlates with future 
cardiovascular (CV) events and total mortality rate 
(13). Moreover, a 2-hour postchallenge glycemia 
during OGTT is not only a better predictor of 
the dysglycemic state than FPG alone but also a 
better risk predictor for subsequent cardiovascular 
complications (5,11). The Funagata Study also reveals 
a higher CV mortality rate in subjects with IGT than 
in those with IFG (15). In three other studies, CV 
mortality rate in individuals with IGT is close to that 
of those with overt type 2 diabetes mellitus (T2DM) 
and much greater than in the subjects with IFG and 
normal glucose tolerance (NGT) (5,6,9). Therefore, 
FPG measurement alone is insufficient for a correct 
recognition of a substantial proportion of individuals 
with abnormal glucose regulation among CAD 
patients. That is why OGTT is recommended for the 
appropriate classification of glucose abnormalities 
in patients at high risk, which includes all the 
individuals with established CV disease. 
The aim of our study was to estimate the 
prevalence of newly-diagnosed glucose abnormalities 
by OGTT among the patients undergoing coronary 
angiography for known or suspected CAD and 
without known glucose abnormalities.
MATERIAL AND METHODS
Our study covered a total of 96 consecutive 
patients without previous history of T2DM 
undergoing coronary angiography at acute or elective 
admission for known or suspected CAD. They were 
78 males (81,25%) and 18 females (18,75) at a mean age 
of 58,2±8,6 years. Anthropometric measurements 
included height, weight, waist circumference and 
calculation of body mass index (BMI). A routine 
OGTT was performed within a week after hospital 
discharge in all of them. Glucose tolerance was defined 
according to WHO-2006 criteria. The patients 
were free of current infections and corticosteroid 
therapy. Data concerning risk factors, medical 
history and concomitant medications were collected. 
Venous plasma was centrifuged immediately after 
blood collection and glucose concentrations were 
determined by hexokinase method at 0 min (FPG) 
and 120 min after glucose load (postchallenge 
glycemia). Glycated hemoglobin (HbA1c) was 
measured by immunoassay for the quantitative 
determination of percentage hemoglobin A1c in 
whole blood samples on the AxSYM System, Abbott, 
USA. Coronary angiographies were evaluated by 
interventional cardiologists, who were not familiar 
with patients’ exact glucometabolic status. 
Statistical analysis was done using GraphPad 
Prism version 5. Data are expressed as means ±SD 
or n (%). Value of p<0,05 was considered statistically 
significant. The study was approved by the Ethical 
Commission of the Medical University of Varna.  
RESULTS
Patients’ mean BMI was 30,1±4,2 kg/m2 and 
waist circumference was 105,6±10,5 cm.
Drug therapy administered at hospital discharge 
was summarized on Table 1. 
Our results showed that glucose disturbances 
prevailed over normoglycemia as 64,58% of the 
patients demonstrated hyperglycemia while 35,42% 
presented with NGT. Overall, 120 min-hypеrglycemia 
(≥7,8mmol/L) was found out in 52,08% of the 
participants and only 12,5% of the cases had isolated 




inhibitors/ angiotensin receptor 
blockers
81 84,37
Table 1. Drug therapy at hospital discharge (n=96)
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fasting hyperglycemia (FPG ≥6,1mmol/L and 
postchallenge glucose <7,8mmol/L). Based on plasma 
glucose values such as FPG and 2-hour post-OGTT 
glucose, the proportion of patients with newly-
diagnosed T2DM, IGT and IFG was 26,04%, 28,12% 
and 10,42 %, respectively. 
Without the postchallenge data provided by 
OGTT, the corresponding prevalence of abnormal 
glucose metabolism was much lower (in 40,63% of 
the cases) (Fig. 1). 
Among the subjects with prediabetes, 72,97% 
had IGT and 27,03% had IFG. Moreover, 48,15% of 
IGT patients were with normal fasting glycemia (<5,6 
mmol/L) and 54,05% of all the patients who met 
the fasting criterion of 5,6-6,9 mmol/L were with 
IGT or diabetes. Mean FPG of IGT individuals was 
slightly but significantly higher compared to NGT 
ones (5,59±0,1 versus 5,26±0,08; p=0,01). However, 
subjects with isolated IGT (FPG <6.1 mmol/L) 
and NGT showed a similar FPG (5,40±0,08 versus 
5,26±0,08; p=0,3) (Fig. 2).
Some 20% of the newly-diagnosed T2DM 
patients reached a diagnostic FPG value only, 
32% reached 120 min.-plasma glucose (PG) value 
only while 48% met combined criteria. Moreover, 
32% of them had HbA1c <6,5%. Mean HbA1c was 
significantly lower in the patients with prediabetes 
than in the patients with newly-detected T2DM 
(5,65±0,07% versus 7,14±0,50%; p=0,001) and similar 
to that in the subjects with NGT (5,65±0,07% versus 
5,46±0,09%; p=0,1). In the patients with HbA1c 
<6,0%, glycated hemoglobin correlated only with 
120’-glycemia (Pr=0,44; p<0,006), while in those 
with HbA1c ≥6,0%, there was a correlation with 
both FPG and 120’-postchallenge glucose (Pr=0,89; 
p<0,0001; Pr=0,69; p<0,0007, respectively).
DISCUSSION
The main findings of our study showed that 
the newly-detected glucose abnormalities in CAD 
patients were more common than normoglycemia. 
Our results are in accordance with previously 
published data about the high incidence rate of 
undiagnosed abnormal glucose tolerance discovered 
by OGTT in angiographied coronary patients 
independently of the size number (1,7,16). In contrast, 
glucose abnormalities were markedly more seldom 
when diagnosis was based on FPG measurement 
only (7). In our contingent, the 2-hour post-OGTT 
hyperglycemia was present in 52,08% of the cases. 
Therefore, FPG estimation alone would misdiagnose 
a substantial proportion of patients with abnormal 
glucose regulation, including diabetes mellitus and 
IGT. Although OGTT is recommended for the clear 
classification of glucose tolerance in these patients 
Fig. 1. Comparison of glucose tolerance defined by OGTT 
(FPG and 120’-postchallenge glucose) or FPG only 
Fig. 2. Comparison of FPG levels between patients with 
IGT, isolated IGT (FPG <6,1 mmol/L) and NGT
Fig. 3. Percentage of HbA1c in patients with newly-detect-
ed T2DM (nT2DM), prediabetes mellitus and NGT
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(2), it has not become a regularly used test in CAD 
population yet. Known or newly-detected T2DM 
is a well-known CV risk factor. Several several 
studies show, however, that IGT and even IFG are 
associated with an increased risk of CV morbidity 
and mortality, too (4,14). The observed positive 
correlation between HbA1c <6,0% and postchallange 
glycemia and substantial proportion of T2DM and 
IGT patients who will remain undiagnosed require a 
routine OGTT. 
We performed OGTT soon after hospital 
discharge without confirmation later on. However, 
data available demonstrated that determination 
of the glycemic status in the patients with acute 
myocardial infarction during hospital stay is reliable 
and reproducible three months later on (10). This 
strongly suggests that OGTT is the most valuable 
tool for the early detection of disturbed glucose 
regulation and should routinely be performed in the 
patients with known or suspected CAD.
CONCLUSION
Glucose abnormalities identified by OGTT are 
more common than normoglycemia - in 64,58% 
versus 35,42% of the patients undergoing coronary 
angiography for known or suspected CAD. In 
addition, more than 50% of subjects present with 
postchallenge hyperglycemia. If the classification of 
glucose abnormalities is done without postchallenge 
data during OGTT, a substantial proportion of 
prediabetic and diabetic disturbances would have 
been not only underestimated but also misclassified. 
This suggests that OGTT should be performed in 
any patients with known or suspected CAD.
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